Cargando…

Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study

OBJECTIVE: Oral once-daily dual-release hydrocortisone (DR-HC) replacement therapy was developed to provide a cortisol exposure−time profile that closely resembles the physiological cortisol profile. This study aimed to characterize single-dose pharmacokinetics (PK) of DR-HC 5–20mg and assess intras...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johannsson, Gudmundur, Lennernäs, Hans, Marelli, Claudio, Rockich, Kevin, Skrtic, Stanko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065076/ https://www.ncbi.nlm.nih.gov/pubmed/27129362 http://dx.doi.org/10.1530/EJE-15-1212

Ejemplares similares

Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency
por: Nilsson, A G, et al.
Publicado: (2014)

Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study
por: Nilsson, Anna G, et al.
Publicado: (2017)

Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone
por: Espiard, Stéphanie, et al.
Publicado: (2020)

Improved salivary cortisol rhythm with dual-release hydrocortisone
por: Ceccato, Filippo, et al.
Publicado: (2018)

SAT302 Circulating And Urinary Metabolites Associated With Total Exposure Of Cortisol And Cortisol Time Profile
por: McQueen, Johanna, et al.
Publicado: (2023)

Chronotherapy based on modified-release hydrocortisone to restore the physiological cortisol diurnal rhythm
por: Whitaker, Martin J., et al.
Publicado: (2022)

Metabolic Effects of Cortisone Acetate vs Hydrocortisone in Patients With Secondary Adrenal Insufficiency
por: Ekstrand, Elise, et al.
Publicado: (2020)

Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
por: deVries, Tina, et al.
Publicado: (2019)

Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food
por: Lamba, Manisha, et al.
Publicado: (2016)

Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency
por: Guarnotta, V, et al.
Publicado: (2019)

The use of prednisolone versus dual-release hydrocortisone in the treatment of hypoadrenalism
por: Choudhury, Sirazum, et al.
Publicado: (2021)

Plasma, salivary and urinary cortisol levels following physiological and stress doses of hydrocortisone in normal volunteers
por: Jung, Caroline, et al.
Publicado: (2014)

Pharmacokinetics of Once‐Daily Extended‐Release Tacrolimus Tablets Versus Twice‐Daily Capsules in De Novo Liver Transplant
por: DuBay, Derek A., et al.
Publicado: (2019)

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2018)

The pharmacokinetics of once-daily dosing with gentamicin in women with postpartum endometritis.
por: Sunyecz, J A, et al.
Publicado: (1998)

Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life
por: Mongioì, L M, et al.
Publicado: (2017)

Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency
por: Bioletto, Fabio, et al.
Publicado: (2023)

Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5‐Lipoxygenase Activating Protein Inhibitor
por: Ericsson, Hans, et al.
Publicado: (2018)

Confounding effects of liquorice, hydrocortisone, and blood contamination on salivary cortisol but not cortisone
por: Imamovic, Marcus, et al.
Publicado: (2022)

A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
por: Alshali, Khalid Z., et al.
Publicado: (2016)

Early Metabolic Benefits of Switching Hydrocortisone to Modified Release Hydrocortisone in Adult Adrenal Insufficiency
por: Bannon, Christopher A. M., et al.
Publicado: (2021)

Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin(®) in Children and Adults
por: Papathanasiou, Theodoros, et al.
Publicado: (2021)

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation
por: Ochoa, Dolores, et al.
Publicado: (2021)

Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2016)

Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2017)

Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson’s disease
por: Yun, Ji Young, et al.
Publicado: (2013)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Tissue Glucocorticoid Metabolism in Adrenal Insufficiency: A Prospective Study of Dual-release Hydrocortisone Therapy
por: Dineen, Rosemary A, et al.
Publicado: (2023)

Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2022)

Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
por: Merke, Deborah P, et al.
Publicado: (2021)

Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain
por: Vandenbossche, Joris, et al.
Publicado: (2012)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
por: Dickinson, L, et al.
Publicado: (2010)

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
por: Moes, D. J. A. R, et al.
Publicado: (2015)

Formulation and Evaluation of Once Daily Minocycline Hydrochloride Extended Release Matrix Tablets
por: Keny, R. V., et al.
Publicado: (2009)

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
por: Oliveira, Lilliana, et al.
Publicado: (2011)

The Effect of Once-Daily Gabapentin Extended Release Formulation in Patients With Postamputation Pain
por: Knezevic, Nebojsa Nick, et al.
Publicado: (2019)

Pharmacokinetic Profile of Lesogaberan (AZD3355) in Healthy Subjects: A Novel GABA(B)-Receptor Agonist Reflux Inhibitor
por: Niazi, Mohammad, et al.
Publicado: (2012)

Once-daily dosing of gentamicin.
por: Soper, D E
Publicado: (1998)

Modified-Release Hydrocortisone: Is It Time to Change Clinical Practice?
por: Stewart, Paul M
Publicado: (2019)

A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity
por: Glick, Lauren, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b633il4mt2p6gljagpj5qoh13c